Nivolumab induced hypopituitarism – case report (CROSBI ID 734143)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Lepetić, Petra ; Linarić, Petra ; Jezernik, Dejana ; Kanceljak, Kristina ; Tečić Vuger, Ana ; Pavlović, Mirjana ; Vazdar, Ljubica ; Šeparović, Robert
engleski
Nivolumab induced hypopituitarism – case report
Nowadays, immune checkpoint inhibitors (ICI) are a treatment of choice in a wide array of malignancies such as RCC, melanoma, or non - small cell lung carcinoma with significantly improved survival rates. Nivolumab targets programmed death 1 receptor (PD-1) - an effector ligand of immune checkpoint pathways, thus promoting an immunological reaction against cancer cells.Many immunerelated adverse effects are due to specific mechanisms of action.Although hypopituitarism is more frequent following combo therapy (ipilimumab with nivolumab), it rarely occurs in monotherapy with nivolumab. This care report aims to demonstrate occasional, but potentially severe entity that requires appropriate prompt diagnostic and therapeutic interventions. Patients should be closely monitored for a wide range of adverse events, keeping in mind that a wide range of immune-related adverse events can occur. Some of them are potentially severe, deferring treatment and compromising outcomes. At that point, prompt and focused care is needed to resolve the complications and to achieve maximum therapeutic potential.
immune checkpoint inhibitors (ICI), programmed death 1(PD-1) receptor, renal cell carcinoma (RCC), hypopituitarism
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
64-64.
2022.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Libri oncologici : Croatian journal of oncology
0300-8142
2584-3826
Podaci o skupu
Nepoznat skup
poster
29.02.1904-29.02.2096